Pancreatic cancer trials

AI-generated summary

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies is being studied. Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer +3 • Eligibility: Inclusion Criteria (Key Factors): 1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: * Participant is intolerant of existing therapy(ies) known…. Goal: RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. Phase/Status/Sponsor: Unknown phase; RECRUITING; RasCal Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases". is being studied. Conditions: Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease +4 • Eligibility: Inclusion Criteria: 1. Patients * diagnosed with chronic liver disease (viral or not) * diagnosed with at least one liver nodule for which a biopsy is planned as…. Goal: Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut National de la Santé Et de la Recherche Médicale, France.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. is being studied. Conditions: Metastatic Solid Tumors, Stage 4 Cancer • Eligibility: Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have…. Goal: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Phase/Status/Sponsor: Unknown phase; RECRUITING; New Phase Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BBO-11818 in Adult Subjects With KRAS Mutant Cancer is being studied. Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma +11 • Eligibility: Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation *…. Goal: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer Metastatic • Eligibility: Inclusion Criteria: * 1\) Men or women aged 18 to 75 years old (including the critical value). * 2）Metastatic pancreatic cancer confirmed by histology or cytology. * 3）Patients…. Goal: This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Yizhong Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors is being studied. Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland +7 • Eligibility: Inclusion Criteria: This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC Procurement Inclusion Criteria 1. The…. Goal: This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Histological or pathological confirmation of metastatic pancreas adenocarcinoma. Cytological or histological evidence of metastatic disease is required. * Male or Female greater than or equal…. Goal: The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Engeneic Pty Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma is being studied. Conditions: Mesothelioma, Thymoma, Pancreatic Neoplasms +2 • Eligibility: * INCLUSION CRITERIA: * All participants greater than or equal to 2 years of age with malignant mesothelioma. * All participants greater than or equal to18 years of…. Goal: Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study is being studied. Conditions: Pancreatic Cancer, PD-L1, PD-1 Inhibitor +2 • Eligibility: Inclusion Criteria: * Age ≥ 18 years, regardless of gender; * ECOG score of 0 to 1; * Patients with histologically or cytologically confirmed pancreatic malignancy; * No…. Goal: To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zhejiang Provincial People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma is being studied. Conditions: Pancreas Adenocarcinoma, Cachexia • Eligibility: Inclusion Criteria: Subject must meet all of the following applicable inclusion criteria to participate in this study: * Written informed consent and HIPAA authorization for release of personal…. Goal: A major complication of pancreatic adenocarcinoma (PDAC) is cancer cachexia (CC) which is a complex syndrome characterized by skeletal muscle mass loss (with or without loss of fat mass) and progressive functional impairment not reversible by conventional nutritional support. It is estimated to occur in over 75% of patients with advanced PDAC, the highest incidence of all solid tumors, and contributes significantly to poor outcomes and mortality. Phase/Status/Sponsor: Unknown phase; RECRUITING; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests precision-based immunotherapy approaches for primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and aims to build a biospecimen repository to study the biology of the cancer and how patients respond to treatment. - It will enroll adults 18 and older with liver cancer who are receiving or planning to receive immunotherapy, and will collect medical records, imaging, tumor tissue, and samples such as blood, urine, and stool over time. - Researchers will perform a wide range of analyses (genomics, epigenetics, metabolomics, microbiome, and immune monitoring) to identify factors that predict response or resistance to immunotherapy and to understand disease progression. - HIV infection is an exclusion criterion, and the study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding durvalumab to the chemotherapy drugs gemcitabine and cisplatin given before surgery helps treat high-risk, resectable intrahepatic cholangiocarcinoma (liver cancer). - It is for adults who are considered candidates for curative surgery. - Researchers want to learn how many patients can complete the pre-surgery therapy and then have the tumor completely removed, as well as rates of major tumor response and overall survival after treatment. - Key exclusions include pregnancy, active autoimmune diseases, active infections (including hepatitis B or C), recent major surgery or current immunosuppressive therapy, and other conditions that could affect safety or results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biobank for Cholestatic Liver Diseases. is being studied. Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma +1 • Eligibility: Inclusion Criteria: PSC * Patients diagnosed with PSC and who are between the age of 18 and 85 at time of enrollment in the study. * The diagnosis…. Goal: This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a phase I dose-escalation trial testing AU409, an RNA transcription modulator, to find the safest and recommended dose and to study its safety in adults with advanced liver cancers or solid tumors that have spread to the liver. Eligible participants are adults 18 and older with an advanced solid tumor that has exhausted standard treatments (or no good options), especially with liver-dominant disease or primary liver cancer; exclusions include untreated brain metastases, serious heart problems, active hepatitis B, pregnancy, or recent anticancer therapy. The study aims to determine the maximum tolerated dose and the recommended phase II dose and to assess safety and how AU409 behaves in the body. It will also look for early signs of anti-tumor activity on imaging and may collect tumor tissue and blood samples for analysis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests BOLD-100 given with the chemotherapy FOLFOX in adults with advanced gastrointestinal cancers (such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) to assess safety and tolerability, using a dose-escalation phase followed by expansion. - In the colorectal cancer arm (Arm VII), eligible patients who are oxaliplatin-naïve and have had only one prior metastatic therapy will be randomized to three groups: BOLD-100 at 500 mg/m2 with FOLFOX, BOLD-100 at 625 mg/m2 with FOLFOX, or FOLFOX alone, with quality-of-life assessments. - The trial aims to learn whether adding BOLD-100 provides anti-tumor activity and how it affects patients’ quality of life, while establishing safe dose levels. - Key exclusions include neuropathy greater than grade 2, CNS metastases, active HIV on ART, DPD deficiency, prior exposure to BOLD-100 (for Arm VII), MSI-H tumors, and recent major treatments or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors is being studied. Conditions: Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer +1 • Eligibility: 1. Willing to sign the informed consent form and follow the requirements specified in the protocol. 2. Life expectancy ≥ 3 months. 3. Tumor specimen available for CDH17…. Goal: This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; ArriVent BioPharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer is being studied. Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF). * Female participant is not pregnant,…. Goal: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial compares rilvegostomig plus gemcitabine and cisplatin versus durvalumab plus gemcitabine and cisplatin as first-line treatment for advanced biliary tract cancer. - It is for adults with unresectable locally advanced or metastatic BTC, including intrahepatic or extra-hepatic cholangiocarcinoma and gallbladder cancer, who have not yet received systemic therapy for advanced disease and have measurable disease with good performance status. - The study aims to learn which regimen provides better efficacy and acceptable safety when used at the start of treatment. - Key exclusions include ampullary cancer, prior systemic therapy for unresectable or metastatic BTC, prior exposure to immune-targeting therapies, active autoimmune disease requiring steroids, and certain interstitial lung disease or serious skin conditions. - Sponsor: AstraZeneca; Status: Recruiting; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is being studied. Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Histologically confirmed diagnosis of any of the following: • Gastric or…. Goal: The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anwaar Saeed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer • Eligibility: Inclusion Criteria 1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC). 2. Locally advanced unresectable or metastatic BTC…. Goal: The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jazz Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers is being studied. Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer +2 • Eligibility: * INCLUSION CRITERIA: * For Phase I: Evaluable, unresectable cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on…. Goal: Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Institutional Registry of Rare Diseases is being studied. Conditions: Rare Diseases, Amyloidosis, Sarcoidosis +23 • Eligibility: Inclusion Criteria: * Clinical and/or molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn…. Goal: The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD). Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hospital Italiano de Buenos Aires.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Gallium-68 FAPI PET/CT to see if it improves detection, staging, and restaging of biliary tract cancers compared with the standard FDG PET/CT. It is for adults 18 and older with suspected or confirmed biliary cancers, including gallbladder cancer, cholangiocarcinoma, or suspected recurrence after treatment. The study will assess how well FAPI detects primary tumors, lymph node involvement, and metastases and whether it changes clinical decisions or reduces the need for invasive procedures. Participants must give informed consent, and those with a concurrent malignancy are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling is being studied. Conditions: Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult +5 • Eligibility: Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers:…. Goal: The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Javier Toledo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Target-specific immunoPET Imaging of Digestive System Carcinoma is being studied. Conditions: Malignancy, Digestive Cancer, Digestive System Neoplasm +12 • Eligibility: Inclusion Criteria: 1. Aged 18-75 years old and of either sex； 2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging; 3.…. Goal: The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated. Phase/Status/Sponsor: Unknown phase; RECRUITING; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Collection of Blood From Patients With Cancer is being studied. Conditions: Prostate Cancer, Breast Cancer, Colon Cancer +2 • Eligibility: * INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2,…. Goal: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests the drug tivozanib for biliary tract cancers (cholangiocarcinoma and gallbladder cancer) in adults who have already had chemotherapy, to find the safest and most effective dose and to learn its overall response rate. It is open-label, non-randomized, and carried out at a single center, using 28-day treatment cycles (3 weeks on, 1 week off) with efficacy checked every 8 weeks. Eligible participants are adults 18 or older with biliary tract cancer not removable by surgery who have had prior first-line chemotherapy and have adequate organ function. Key exclusions include prior tivozanib use, pregnancy, and significant cardiovascular disease or uncontrolled hypertension.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer is being studied. Conditions: Locally Advanced Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: 1. Patient aged from 18 to 75 years at the date of signature of the consent form 2. Histologically or cytologically proven pancreatic adenocarcinoma 3. Eastern…. Goal: The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut du Cancer de Montpellier - Val d'Aurelle.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This multicenter, open-label, single-group trial tests photodynamic therapy using Cosiporfin Sodium together with gemcitabine and cisplatin (GC) for people with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma that cannot be operated on. - It aims to preliminarily measure efficacy, focusing on the 6-month overall survival rate, and to assess safety and tolerability of the PDT plus GC treatment in patients with biliary obstruction. - Eligible participants are adults with histologically confirmed disease, inoperable or unwilling to have surgery, with biliary obstruction and at least one measurable lesion outside the bile ducts, plus good performance status and adequate organ function. - Key exclusions include ampullary cancer, brain metastases, major liver tumor burden (>50%), prior exposure to photosensitizers or PDT, prior systemic therapy in the recurrent/metastatic setting, unremovable biliary stents, active infections, and other conditions that could interfere with treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma is being studied. Conditions: Pancreatic Adenocarcinoma Metastatic • Eligibility: Inclusion Criteria: 1. Capable of giving signed informed consent. 2. Male and female participant aged 18 years and older. 3. Participants must have histologically or cytologically confirmed PDAC:…. Goal: This is a Phase 1b dose escalation trial of OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate (ADC), in combination with gemcitabine/nab-paclitaxel and tislelizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will be conducted in two parts (Part 1 and Part 2). Phase/Status/Sponsor: Unknown phase; RECRUITING; Oncomatryx Biopharma S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) is being studied. Conditions: Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer • Eligibility: Inclusion Criteria: 1. Patients with cytologically or histologically confirmed BTC by AJCC version 8. 2. Patients must have late stage (locally advanced, recurrent or metastatic) BTC. Patients must…. Goal: This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nataliya Uboha.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer is being studied. Conditions: Liver Cancer, Emotional Disorder • Eligibility: Inclusion Criteria: * Age between 18 and 75 years, inclusive, regardless of gender. * Presence of at least one radiologically measurable lesion according to the Response Evaluation Criteria…. Goal: Hepatocellular carcinoma (HCC) carries a poor prognosis, with limited efficacy from current therapies including immune checkpoint inhibitors (ICIs). Concurrently, emotional distress (ED) is highly prevalent in cancer patients and is implicated in tumor progression via neuroendocrine-immune axis dysregulation (e.g., HPA axis activation, immunosuppressive TME). Phase/Status/Sponsor: Unknown phase; RECRUITING; Tongji Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether objectively measured physical activity, collected with wearables, is linked to ECOG performance status and overall survival in adults with advanced cancer. - It is for adults with various advanced cancers who live in the Houston area and can participate in English. - The trial also looks at whether wireless data collection and transfer into the CYCORE system is feasible and acceptable in real-world cancer care. - Key exclusions include recent major surgery, certain cognitive or unstable heart/lung conditions, lack of home internet/WiFi, pregnancy, pacemakers, or current enrollment in conflicting protocols.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests antibody-drug conjugate (ADC) drugs, used alone or in combination with HRS-4642 or immunotherapy, in adults with unresectable locally advanced or metastatic pancreatic cancer. - It is an open, single-center study with two stages: a dose exploration phase to find a safe, potentially effective dose, followed by an efficacy exploration phase. - The study aims to learn about safety, tolerability and preliminary efficacy to determine the recommended dose for future study (RP2D). - Eligible participants are adults 18–75 with advanced pancreatic cancer and measurable disease, good performance status, and adequate organ function; key exclusions include allergy to the investigational drug, active CNS metastases, HIV or active hepatitis infections, recent systemic therapy or major surgery, and other conditions that could affect participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intravital Microscopy in Human Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm +20 • Eligibility: Inclusion Criteria: * Age ≥ 18 years of age * Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2 * Measurable tumor by direct visualization requiring surgical resection…. Goal: This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer is being studied. Conditions: Pancreatic Neoplasm • Eligibility: Inclusion Criteria: \- Histologically confirmed pancreatic cancer without distant metastasis. Not eligible for surgery or systemic chemotherapy, defined as: Clinical Frailty Scale (CFS) score ≥ 4, or Significant…. Goal: "This prospective, single-arm phase II study aims to evaluate the efficacy and safety of carbon ion radiotherapy in frail patients with histologically confirmed, non-metastatic pancreatic cancer who are not eligible for surgery or systemic chemotherapy. Frail status is defined as a Clinical Frailty Scale (CFS) score ≥4 or the presence of significant medical comorbidities limiting aggressive treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Yonsei University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether ivonescimab is more effective than the standard second‑line chemotherapy FOLFOX for adults with advanced biliary tract cancer who progressed after first‑line treatment and who participated in SAFIR-ABC10. Participants are randomized 2:1 to receive ivonescimab every 3 weeks or FOLFOX, with the ivonescimab arm limited to up to 34 cycles. Treatments continue until disease progression or until the study limits are reached, and tumor responses are checked by imaging roughly every 6 weeks using RECIST v1.1. Key exclusions include contraindication to ivonescimab, unresolved toxicities from prior therapy, and conditions such as active HIV or TB, active autoimmune disease requiring systemic treatment, pregnancy, or recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma. is being studied. Conditions: Intrahepatic Cholangiocarcinoma (Icc) • Eligibility: Inclusion Criteria: * Histologically confirmed ICC (clinical stage I-III). * Undergoing curative-intent hepatectomy. * Availability of preoperative pasma or serum sample (≥200 µL). * Standard staging imaging completed…. Goal: Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes is being studied. Conditions: Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms +76 • Eligibility: Inclusion Criteria: * Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study…. Goal: Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Phase/Status/Sponsor: Unknown phase; RECRUITING; Cedars-Sinai Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether contrast-enhanced ultrasound (CEUS) can be used to evaluate how hepatocellular carcinoma (HCC) responds after transarterial radioembolization (TARE). - It is for adults with treatment-naïve HCC who are scheduled to undergo TARE. - The study will compare CEUS results with standard CT or MRI at about 1–2 months and 4–6 months post-TARE to see if CEUS can detect viable tumor earlier. - About 30 patients will be enrolled over 18 months across Jefferson Health sites, with at least 6 months of follow-up. - Exclusion criteria include medical instability or serious illness and known sensitivities to the ultrasound contrast agents Lumason or Sonazoid.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This randomized, multicenter trial tests UI-EWD (Nexpowder) hemostatic powder as the initial treatment, compared to conventional endoscopic therapies for nonvariceal upper GI bleeding. - It is for adults 22 years and older who have acute overt upper GI bleeding seen on endoscopy from ulcers with active bleeding or a visible vessel, tumors with bleeding, Dieulafoy lesions, or Mallory-Weiss tears. - The study aims to determine whether UI-EWD is noninferior to traditional therapy in stopping bleeding and reducing rebleeding when used first. - Key exclusions include pregnancy or nursing, inability to consent, recent endoscopic hemostatic treatment within 30 days, triple antithrombotic therapy, very low platelet count (<50 x 10^9/L), high INR (>3.5), and endoscopy not performed within 36 hours.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests the molecular and genetic basis of pediatric liver cancer by analyzing tumor tissue, blood, and saliva from affected children and their biological parents and siblings. It is for children under 21 who have had a liver tumor (benign or malignant) and their families. Researchers aim to learn how gene defects and gene function influence how these cancers develop and behave, to improve classification and future treatments. Exclusions include no prior or current treatment for a childhood liver tumor, and non-biological guardians or non-biological siblings.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * An adult 18 to 100 years of age, * Able to read English or Spanish at least an eighth-grade level, * From a racial/ethnic background…. Goal: The purpose of this study is to pilot test and evaluate an existing tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adult cancer patients and their family members through referral to cancer clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a 3D biliary tract reconstruction tool and an AI algorithm to help endoscopists perform ERCP by creating 3D models from MRCP and CT scans. - It is for adults with biliary strictures who are treated with ERCP at Saint Antoine Hospital or Henri Mondor Hospital. - The study is retrospective and uses imaging data collected during routine care to develop and validate the software. - The goal is to see if the 3D models improve visualization and navigation during ERCP, with performance assessed by image-quality metrics and localization error, and without changing patient management. - Exclusion: patients who do not consent to reuse their data for research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures is being studied. Conditions: Painless Gastrointestinal Endoscopy • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years, regardless of sex; * Patients scheduled to undergo painless gastrointestinal endoscopy examination or endoscopic surgery, which must include upper…. Goal: Gastrointestinal endoscopy procedures, including upper gastrointestinal endoscopy and colorectal endoscopy, represent a fundamental and important method for examining and managing digestive tract diseases, with both diagnostic and therapeutic applications. They are also utilized as effective tools for surveillance of gastrointestinal tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Jiao Tong University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer is being studied. Conditions: Advanced Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8 +4 • Eligibility: Inclusion Criteria: * Documented informed consent by the participant * Willingness to provide tissue and blood samples for correlative studies * Age: \>= 18 years * Eastern Cooperative…. Goal: This phase II trial studies the effects of lenvatinib and pembrolizumab maintenance therapy in treating patients with pancreatic cancer that has spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma is being studied. Conditions: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study…. Goal: This is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Medical University of South Carolina.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC) is being studied. Conditions: Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * A patient will be eligible for inclusion in this study if he or she meets all of the following criteria: 1. 18 years of age…. Goal: Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This early-phase trial tests a treatment for unresectable liver cancer using a patient’s own dendritic cells plus the Prevnar vaccine, given with immune checkpoint inhibitors after high-dose external beam radiotherapy. - It includes adults with hepatocellular carcinoma or intrahepatic cholangiocarcinoma that cannot be removed and have been treated with EBRT, with dendritic cells injected into the tumor and vaccines given alongside atezolizumab plus bevacizumab or atezolizumab plus tiragolumab. - The study aims to evaluate safety and tolerability and to estimate progression-free survival and other outcomes to see if this approach can stimulate the immune system and slow the cancer, compared with historical data. - Key exclusions include pregnancy or breastfeeding, immunocompromised status (including HIV), active infection or uncontrolled illness, autoimmune disease (with some exceptions), inability to stop anticoagulants for injections, and advanced liver disease (Child-Pugh B/C) or prior immune-modulating therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Comprehensive Care of Cancer Patients is being studied. Conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer • Eligibility: Inclusion Criteria: * For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2)…. Goal: Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: 1. Subjects voluntarily participate in this study, sign the informed consent form; 2. Age ≥18 years and ≤75 years; 3. Histologically or cytologically confirmed pancreatic ductal…. Goal: This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer Phase/Status/Sponsor: Unknown phase; RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System is being studied. Conditions: Cancer, Cancer Central Nervous System, Cancer Thoracic +5 • Eligibility: Inclusion Criteria: * Able to comprehend and be willing to sign an informed consent form (ICF). * Diagnosis of local, loco-regionally advanced, or metastatic malignancy for whom radiotherapy…. Goal: The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), or SCINTIX Biology-guided radiotherapy (BgRT) in standard of care (SOC) use in the treatment of local,loco-regionally advanced, and oligometastatic malignancies. In addition, patient costs and charges will be analyzed to quantify the health economic impact of this modality. Phase/Status/Sponsor: Unknown phase; RECRUITING; RefleXion Medical.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Agrees to follow the trial protocol and visit schedule, has signed informed consent; 2. Subjects must be ≥18 years of age at time of informed…. Goal: This is a first-in-human, single-arm, open-label, dose escalation prospective phase I clinical study to evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Alone in patients with Unresectable, Metastatic or Advanced pancreatic cancer or Non-small Cell Lung Cancer(NSCLC) after Standard Treatment Failure. The primary objective is to evaluate the safety and tolerability of TMT101 Injection as monotherapy in patients with advanced pancreatic cancer and NSCLC, and to determine the recommended therapeutic dose (RD) of TMT101 Injection as monotherapy Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a two-step, neoadjuvant treatment for intrahepatic cholangiocarcinoma (ICC): 12 weeks of capecitabine plus Selective Internal Radiation Therapy (SIRT) with Yttrium-90, given before surgery. - The goal is to see if this approach can shrink or downstage tumors so surgery is more feasible and potentially more successful, compared with upfront surgery. - It is for adults with histologically confirmed ICC that surgeons consider resectable but at high risk for close margins; key exclusions include severe liver disease or poor organ function, prior ICC chemotherapy, contraindication to hepatic artery catheterization, pregnant status, and other active cancers. - Participants are randomly assigned to the experimental neoadjuvant treatment or to the standard approach of immediate surgery, with long-term follow-up to compare outcomes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a French multicenter, retrospective, observational study that is currently recruiting to study rare primary liver cancers. It includes adults 18 and older with histologically confirmed hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma diagnosed after January 1, 2018. The study aims to describe clinical, histological and radiological features, collect tumor tissue and blood, and evaluate how treatments used in real-world care have performed to help determine the best sequencing of therapies. Key exclusions are lack of social security and no access to tumor tissue; living participants must consent to research for ancillary studies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer is being studied. Conditions: Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic • Eligibility: Inclusion Criteria 1. Adults (aged 18 or more at enrollment) 2. Histologically or cytologically proven pancreatic or colorectal cancer. Histologies may include listing of adenocarcinoma, poorly differentiated carcinoma,…. Goal: Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Phase/Status/Sponsor: Unknown phase; RECRUITING; HealthPartners Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients is being studied. Conditions: Metastatic Pancreatic Cancer • Eligibility: Inclusion Criteria: 1. Male or female aged 18 to 75 on the date the consent is signed. 2. Histologically or cytologically proven metastatic pancreatic adenocarcinoma. The definitive diagnosis…. Goal: The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox alone in patients treated in first metastatic line pancreatic cancer Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut du Cancer de Montpellier - Val d'Aurelle.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer is being studied. Conditions: Liver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer +2 • Eligibility: The following criteria must be met for subjects to be considered for the trial. Additional exclusion criteria must be met for subjects interested in the HepQuant subset of…. Goal: This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Montefiore Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers is being studied. Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms • Eligibility: Inclusion Criteria: * Measurable locally advanced, recurrent, or metastatic biliary tract carcinoma (including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma). * Patients with locally advanced disease…. Goal: This is a Phase 2 study to evaluate the efficacy, using objective response rate, of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous Tumor Infiltrating Lymphocytes (TIL) and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic biliary tract cancer. These are low-incidence cancers carry a poor prognosis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Udai Kammula.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer is being studied. Conditions: Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer +5 • Eligibility: Inclusion Criteria: * Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable peritoneal carcinomatosis * Estimated…. Goal: The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital, Ghent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quality of Care in Relationship to Aborted Cancer Surgery is being studied. Conditions: Cancer, Gastrointestinal Cancer • Eligibility: Inclusion Criteria: * \>18 years * cancer patients with different gastrointestinal cancer diagnosis Exclusion Criteria: \- not able to answer the questionnarie SCNS-SF34 in Swedish.. Goal: Surgery is often a central curative treatment for gastrointestinal tumors. Surgical treatment of diagnosed cancer tumors is decided after a comprehensive assessment of the patient's physical status, radiological assessments and after careful evaluation at the multidisciplinary conference. Phase/Status/Sponsor: Unknown phase; RECRUITING; Linkoeping University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer is being studied. Conditions: Advance Pancreatic Cancer • Eligibility: Inclusion Criteria: * a. Age ≥18 years, ECOG performance status ≤2, and expected survival of ≥3 months. * b. Patients with histologically or cytologically confirmed advanced metastatic pancreatic…. Goal: The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG regimen, thereby improving the prognosis of patients with advanced metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Du Juan.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a CLDN18.2-targeted PET imaging probe to visualize CLDN18.2 expression in tumors, using PET/MR or PET/CT, and also in healthy volunteers for safety. - It includes adults with suspected or confirmed gastric, pancreatic, bile duct, or other CLDN18.2-expressing cancers, plus healthy volunteers for pharmacokinetic study. - In cancer patients, the trial will assess how well CLDN18.2 PET detects tumor lesions, compare findings with histopathology, map location and metabolic features, and explore its use for guiding treatment decisions and predicting response versus FDG PET. - Exclusions include inability to complete scans, allergies to the imaging agent, significant comorbidities, and high fasting glucose (above 11.0 mmol/L) before FDG injection.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of LNCB74 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer +3 • Eligibility: Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed…. Goal: This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; NextCure, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of GC203 TIL in Advanced Malignant Solid Tumors is being studied. Conditions: Solid Tumor, Gynecologic Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * 1\. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures. 2\. Patients must be ≥18…. Goal: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Juncell Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Role of Microbiota in Pancreatic Cancer and Precursor Lesions is being studied. Conditions: Pancreatic Cancer, Microbiome • Eligibility: Inclusion Criteria: * Patients with a suspected lesion (solid/cystic) in the pancreas undergoing diagnostic or therapeutic endoscopic procedure * Age of 18 years or above * Signed informed…. Goal: This is a prospective observational study aiming to investigate the microbiome in patients suspected of having pancreatic cancer. The purpose is to enhance diagnostic accuracy by developing screening protocols for high-risk individuals, identifying specific microbial biomarkers, and improving prognostic criteria to optimize treatment response. Phase/Status/Sponsor: Unknown phase; RECRUITING; Herlev Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms is being studied. Conditions: Pancreatic Cyst • Eligibility: Inclusion Criteria: * Men and women aged \>18 years * Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection * Able to provide informed consent…. Goal: The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a streamlined approach to transarterial radioembolization (TARE) for liver cancer, using SIR-Spheres in a same-day, single-session procedure without full pre-procedural nuclear imaging for eligible patients. - It is for adults with metastatic liver cancer or cholangiocarcinoma whose largest tumor is 7 cm or smaller, up to five tumors, enough healthy liver tissue, good liver function (Child-Pugh A), and good performance status (ECOG ≤1). - The study aims to determine if this faster method can be safely delivered, with predefined dosing rules (lung shunt assumed 5%, lung dose ≤10 Gy) and post-treatment dosimetry the next day, followed for one year. - Exclusions include hepatic vein invasion or hepatic vein enhancement, dysmorphic intratumoral vessels >3 mm, TIPS, major portal vein issues, biliary stents, allergy to contrast, or other factors that could raise the risk of radiation pneumonitis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer is being studied. Conditions: Pancreas Cancer • Eligibility: Inclusion Criteria: * ECOG PS 0-1 * Pathological tissue-confirmed unresectable locally advanced pancreatic cancer * Pancreatic cancer patients who have not received systemic anti-tumor therapy * Primary pancreatic…. Goal: Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shandong Cancer Hospital and Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study is being studied. Conditions: Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma, Perihilar +6 • Eligibility: Inclusion Criteria: * person older than 18 years, who has known extrahepatic cholangiocarcinoma and is indicated for ERCP Exclusion Criteria: * disagreement with the study. Goal: Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital Olomouc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pancreatic Cancer and Diabetes Mellitus is being studied. Conditions: Pancreatic Cancer, Surgery, Diabetes Mellitus • Eligibility: Inclusion Criteria: 1\. male or female Chinese subjects; 2. Age ≥ 18 years; 3. patients with pancreatic cancer who are proposed to undergo pancreatectomy by pancreaticobiliary surgery at…. Goal: The goal of this observational study is to learn about post-surgery of pancreatic cancer diabetes mellitus.The main questions it aims to answer are: 1. Are the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) after pancreatic cancer of different etiologies the same? Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Changzheng Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Metastatic Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the pancreas. * Measurable or evaluable disease per RECIST 1.1. * Previously treated with first-line systemic therapy for unresectable/advanced…. Goal: The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, the investigators propose an open label phase I/II clinical trial of ONT01 with gemcitabine and nab-paclitaxel in unresectable pancreatic ductal adenocarcinoma prior to future studies incorporating anti-PD1 checkpoint immunotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a first-line treatment for unresectable intrahepatic cholangiocarcinoma using FOLFOX-based hepatic arterial infusion chemotherapy with donafenib and pucotenlimab. - It is a prospective, open-label, single-arm phase II study and is not yet recruiting. - The primary goal is to measure the objective response rate, with secondary goals including progression-free survival, overall survival, disease control rate, and safety. - Eligible participants are adults up to 75 years old; key exclusions include prior anti-PD-1/PD-L1 therapy, active CNS metastases, autoimmune disease requiring systemic treatment, active infection, HBV DNA > 2000 IU/mL, HIV, syphilis, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests PSMA-targeted imaging and PSMA expression in biopsy tissue for patients with newly diagnosed gastroenterologic tumors. It aims to see if PSMA-PET can detect more disease sites than standard imaging and whether the PSMA signal can predict outcomes under guideline-based treatment. Eligible participants are adults with newly diagnosed GET before starting guideline-compatible anti-tumor therapy, with available tumor tissue and the ability to consent and follow up. Exclusions include curative-intent treatment, insufficient tumor tissue, history of other cancers, pregnancy or breastfeeding, contraindications to PET/CT, and men with prostate cancer. The study is sponsored by Würzburg University Hospital and is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors is being studied. Conditions: Esophageal Cancer, Gastric Cancer, Pancreatic Cancer +2 • Eligibility: Inclusion Criteria: 1. Voluntarily sign the informed consent and follow the requirements of the protocol; 2. No gender limit; 3. Age: ≥18 years old and ≤75 years old…. Goal: This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sichuan Baili Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories is being studied. Conditions: Bile Duct Adenocarcinoma, Bile Duct Carcinoma • Eligibility: Inclusion Criteria: 1. Provision to sign and date the consent form; 2. Adult patients ≥ 21 years old; 3. Any patient who is required to undergo endoscopic retrograde…. Goal: This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures. The purpose of this research is to assess whether the Dragonfly™ Pancreaticobiliary Scope functioned as intended in combination with the commercially available accessories during your scheduled endoscopy procedure. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Colorado, Denver.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Characteristics of Intestinal Microbiome Following Pancreatic Surgery is being studied. Conditions: Pancreatic Cancer, Microbiota, Pancreatoduodenectomy • Eligibility: Inclusion Criteria: * Adults (aged equal to or greater than 18 years) having had pancreatoduodenectomy (Whipple's) surgery between April 2018 - December 2023 for curative intent and received…. Goal: The goal of this observational study is to learn about intestinal microbiome structure and function in individuals who have undergone a pancreatoduodenectomy and compare to healthy matched controls. The primary objectives of the study are: 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; Royal Prince Alfred Hospital, Sydney, Australia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests capecitabine as maintenance therapy after standard adjuvant chemotherapy for people with resectable pancreatic cancer, and will see if ctDNA-MRD testing can guide which maintenance treatment to use. It is for adults (18+) with pancreatic ductal adenocarcinoma who had an R0 resection within the last 3 months and have no distant metastasis (M0) plus good performance status (ECOG 0-1). The study is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and is currently recruiting. Key exclusions include prior treatment for pancreatic cancer, locally advanced or metastatic disease, significant organ dysfunction or other active cancers within the past 5 years, and other conditions that would make participation unsafe.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer Metastatic • Eligibility: Inclusion Criteria: 1. The patient fully understands this study, voluntarily participates and signs an informed consent form (ICF); 2. Age ≥ 18 years old and ≤ 80 years…. Goal: The purpose of this clinical trial is to explore the efficacy and safety of Regorafenib combined with Toripalimab and Paclitaxel-albumin in patients as the third line treatment for patients with unresectable or metastatic pancreatic cancer.The main question it aims to answer is: Phase Ib: Evaluate the maximum tolerated dose (MTD) of regorafenib and/or phase II clinical recommendations Dose (RP2D). Phase II: Evaluation of the efficacy and safety of Regorafenib Combined with Terriptylimab and Albumin Paclitaxel for Late Third Line Treatment for pancreatic cancer patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer is being studied. Conditions: Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer +1 • Eligibility: Inclusion Criteria: Age 18-75 years at time of enrollment; Histologically or cytologically confirmed advanced or metastatic biliary tract adenocarcinoma (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder carcinoma); Unresectable locally…. Goal: Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help patients live longer without their cancer getting worse. Phase/Status/Sponsor: Unknown phase; RECRUITING; First Affiliated Hospital of Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) is being studied. Conditions: Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: 1. Subject has been informed about the nature of the study, has agreed to participate in the study, and has signed the informed consent form before…. Goal: The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. This type of treatment approach is called total neoadjuvant therapy (TNT). Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer is being studied. Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer • Eligibility: Inclusion Criteria: * Patient must be \>= 18 years of age * Patient must have a histologically confirmed diagnosis of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) at the local laboratory…. Goal: This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer is being studied. Conditions: Advanced Gastric and Pancreatic Cancer • Eligibility: Inclusion Criteria: 1. Age 18-70 years (inclusive) at the time of informed consent; sex unrestricted. 2. Voluntary participation: the subject (or legally authorized representative) must provide written informed…. Goal: The goal of this clinical trial is to learn if CBG131 works to treat advanced gastric cancer or pancreatic cancer in adults whose tumors are CLDN18.2-positive. It will also learn about the safety of CBG131 and find the best dose to use. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; First Affiliated Hospital of Wenzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests a combination of NALIRIFOX chemotherapy and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer. It includes adults up to 75 years old and compares two timing options: early SBRT after 1 cycle of NALIRIFOX or late SBRT after 6–8 cycles. The main goal is to measure progression-free survival, with secondary aims including response rates, disease control, overall survival, and safety. About 42 participants are planned, and the study is not yet recruiting. Eligibility excludes pregnant individuals, those with active infections or uncontrolled illnesses, prior other cancers (with some exceptions), and people with allergies to the study drugs or to liposomal formulations.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer (BTC) • Eligibility: Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study: 1. No gender restriction, age ≥18 years, and expected survival ≥3 months;…. Goal: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the impact of Yueju Pill on quality of life and treatment efficacy in patients with advanced biliary tract cancer (BTC) receiving standard therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: * Selection criteria includes patients with unresectable and borderline resectable and medically inoperable pancreatic cancer that will receive neoadjuvant chemotherapy followed by chemoirradiation. * No prior…. Goal: The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Clinica Universidad de Navarra, Universidad de Navarra.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution is being studied. Conditions: Immune Evasion, Tumor, Pancreas Cancer • Eligibility: Inclusion Criteria: * Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases * Primary PDAC * Patients with benign pancreatic tumors * IPMN patients diagnosed by…. Goal: The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. This project aims to establish a large, multi-center pancreatic cancer cohort and a standardized clinical sample repository, capturing multimodal immunity big data on pancreatic cancer occurrence, progression, and treatment response across the spatial dimension of "peripheral versus local" and the temporal dimension of "tumor evolution/pre- and post-treatment." By integrating patient imaging and clinical information, the investigators will develop a technical platform for intelligent extraction and fusion analysis of cross-scale, multimodal data, thereby mapping the immunity landscape of pancreatic cancer evolution, identifying characteristic changes in immunity parameters, and devising an AI model for early pancreatic cancer diagnosis with high accuracy and robust generalization capabilities, while also exploring the model's interpretability. Phase/Status/Sponsor: Unknown phase; RECRUITING; First Affiliated Hospital of Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma is being studied. Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer • Eligibility: Inclusion Criteria: -Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. *…. Goal: This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Phase/Status/Sponsor: Unknown phase; RECRUITING; Ashish Manne.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas is being studied. Conditions: Pancreas Adenocarcinomas • Eligibility: Inclusion Criteria: * CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT; * Adult patient: age ≥ 18 years; * Patient affiliated with a social security…. Goal: Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic resonance imaging sequences, such as high resolution applied to diffusion sequences (Harder et al., 2022) or magnetic resonance elastography (MRE) (Steinkohl et al., 2021), could help address this issue. Phase/Status/Sponsor: Unknown phase; RECRUITING; Central Hospital, Nancy, France.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether combining bile-based molecular testing with standard biliary brush cytology/biopsy can improve detection of malignant biliary strictures. It is for adults aged 18–90 who have indeterminate biliary strictures and have undergone ERCP with biliary biopsy and/or brush cytology. Researchers will collect bile and screen for molecular markers using multi-omics to develop and validate a bile-based diagnostic model. Exclusions include coagulation disorders, pregnancy, other cancers not related to biliary strictures, or those who decline participation. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Metastatic Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Have histologically or cytologically confirmed PDAC that is metastatic. * Have not been previously treated for PDAC in the metastatic setting. 1. Prior neoadjuvant and/or…. Goal: The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Arcus Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study is a prospective randomized trial comparing two ERCP cannulation techniques: Precut needle-knife precut versus the Intentional Double Guidewire Technique. It targets adults with biliary obstruction who need ERCP and have a native papilla with difficult cannulation (per ESGE 5-5-2). The goal is to learn which method provides better biliary access and has a safer profile during difficult cannulation. Eligible participants are adults over 18 with benign or malignant obstruction and no prior sphincterotomy; key exclusions include ampullary mass, surgically altered anatomy, uncorrectable coagulopathy, or acute pancreatitis before ERCP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer Metastatic • Eligibility: Inclusion Criteria: 1. Age ≥18 years; 2. Histologically or cytologically confirmed unresectable metastatic pancreatic cancer; 3. No prior systemic anti-tumor therapy for metastatic pancreatic cancer. Neoadjuvant or adjuvant…. Goal: Study design: This is a single-arm, open-label, dose-escalation and dose-expansion clinical study to evaluate the safety and efficacy of multiple doses of SapDM275 tumor vaccine injection in combination with the AG regimen for the treatment of patients with metastatic pancreatic cancer who have not received prior systemic anti-cancer therapy and are planned to receive AG as first-line treatment. Treatment must be initiated within 7 days after enrollment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; The Third Xiangya Hospital of Central South University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. is being studied. Conditions: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated • Eligibility: Inclusion Criteria: 1. Metastatic and/or unresectable advanced colorectal adenocarcinoma, or locally advanced, recurrent, metastatic and/or unresectable advanced biliary tract carcinoma 2. HER2 positive or HER2 gene mutation; 3.…. Goal: To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Pharmaceuticals Holding Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding peginterferon alfa-2b to standard nucleos(t)ide analogue therapy can reduce recurrence of HBV-related liver cancer after radical treatment. - It is for adults aged 18-70 who are HBV surface antigen positive and have hepatocellular carcinoma treated with surgery or ablation, with good liver function (BCLC 0-A, Child-Pugh A). - The study is single-center, non-randomized, open-label, comparing NAs alone versus NAs plus peginterferon alfa-2b to see if it lowers the 3-year recurrence rate and may improve cure. - Participants will undergo regular imaging and blood tests every few months to monitor recurrence and safety. - Key exclusions include prior systemic cancer treatments, other active cancers, allergy to interferon, severe liver or kidney disease, autoimmune disease, pregnancy, or participation in other trials.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator will collect real-world data on using direct cholangiopancreatoscopy, performed by a single operator, for biliary and pancreatic duct problems. It will enroll adults undergoing this procedure at participating centers starting June 1, 2025. The study aims to confirm technical feasibility, assess effectiveness and safety, and evaluate cost-effectiveness to determine where in the clinical pathway this technique should be used. Eligibility requires age 18 or older, signed informed consent, and the ability to follow up; those under 18, without consent, or with follow-up is not possible are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas is being studied. Conditions: Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Patients ≥ 18 years old * Pancreaticoduodenectomy for pancreatic adenocarcinoma or distal cholangiocarcinoma * Patient's non-opposition to the reuse of data Exclusion Criteria: * Neoadjuvant…. Goal: Distal cholangiocarcinoma and pancreatic adenocarcinoma are aggressive cancers with overlapping diagnostic features, making them challenging to differentiate. Although both require similar surgical treatment, their postoperative chemotherapy regimens differ significantly, with capecitabine used for distal cholangiocarcinoma and modified FOLFIRINOX for pancreatic adenocarcinoma, based on distinct guidelines. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University Hospital, Bordeaux.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests pimitespib in combination with imatinib for patients with gastrointestinal stromal tumors (GIST) that have progressed on imatinib. - It has a dose-escalation part to find the maximum tolerated dose and the recommended dose, while assessing safety, pharmacokinetics, and early antitumor activity, followed by an expansion part with three arms. - Arm A evaluates the combination in patients who progressed on imatinib at doses below the determined MTD; Arm B tests pimitespib alone and also explores giving imatinib after pimitespib; Arm C uses sunitinib monotherapy as a reference. - Eligibility includes histologically confirmed GIST, radiographic progression on or after imatinib, at least one measurable lesion, and ECOG 0-1 with informed consent. - Exclusion criteria include severe vision impairment, prior therapy beyond imatinib for advanced GIST, prior extensive gastrectomy or small-bowel resection, serious illness, other active cancers, and pregnancy or lactation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer is being studied. Conditions: Metastatic Pancreatic Cancer • Eligibility: Inclusion Criteria: * Voluntarily participate in the study and sign the informed consent form. * Male or female aged 18-80 years (inclusive) at the time of signing the…. Goal: This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fluorouracil or gemcitabine, and either progressed on or were intolerant to the last treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Genfleet Therapeutics (Shanghai) Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is being studied. Conditions: Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer +3 • Eligibility: Diagnosis and Main Criteria for Inclusion/Exclusion: Inclusion Criteria Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the…. Goal: This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Rottapharm Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers is being studied. Conditions: Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly +8 • Eligibility: Inclusion Criteria: * Age ≥65 years * Histologically confirmed non-metastatic or locally advanced gastrointestinal cancers (esophageal, gastric, colorectal, pancreatic, biliary tract) * Planned to receive adjuvant chemotherapy (standard…. Goal: This study evaluates the effectiveness of the G8 and VES-13 frailty scales in predicting chemotherapy-related toxicity in older patients with gastrointestinal cancers receiving adjuvant chemotherapy. Older adults are more vulnerable to treatment-related side effects due to age-related declines in physiological reserve. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Ankara Etlik City Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests how liver cancer (hepatocellular carcinoma, HCC) patients respond to interventional therapy combined with systemic therapy and how outcomes vary between individuals. It will look at outcomes like disease control, progression-free survival, patient-reported outcomes, and adverse reactions, and it will study clinical features and biomarkers that relate to this heterogeneity. The goal is to build a machine learning model to predict the risk of adverse reactions to help tailor decisions for each patient. The study is not yet recruiting and will enroll adults with HCC who are receiving or planning interventional therapy with systemic treatment (including DEB-TACE with targeted therapy and/or immunotherapy) or other local interventional treatments; it excludes people with other active cancers, severe cognitive impairment, very limited life expectancy, or decompensated liver function (Child-Pugh C).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery is being studied. Conditions: Colon Cancer, Gastrointestinal Cancer • Eligibility: Inclusion Criteria: 1. Recently diagnosed with nonmetastatic GI cancer, including but not limited to small bowel, colon, rectal, pancreatic, gastric, or hepatic malignancies, and scheduled for an elective…. Goal: To measure the efficacy of postbiotic supplements in mitigating the gut dysbiosis induced by colon cancer surgery. Efficacy in mitigating dysbiosis will be measured by the change in fecal Shannon Diversity Index (SDI) within patients from the baseline sample to various postoperative timepoints. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer is being studied. Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 +3 • Eligibility: Inclusion Criteria: * Capable of giving written informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: This phase II trial studies the effects of gemcitabine, nab-paclitaxel, durvalumab, and oleclumab in treating patients with primary pancreatic cancer that may be able to be removed by surgery (resectable/borderline resectable). Chemotherapy drugs, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma +23 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined…. Goal: This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding the antidepressant fluoxetine to immunotherapy improves outcomes for people with advanced liver and gallbladder cancers. It is for adults 18 to 80 who have liver cancer or bile duct cancer that has spread or is locally advanced and who are about to start PD-1/PD-L1 inhibitor therapy, and who have depression or anxiety. The researchers want to learn if fluoxetine can better control the cancer, extend survival, and also improve mood and quality of life. Exclusions include active hepatitis B or C infection, a history of serious mental illness, fluoxetine allergy, or inability to take oral medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

EUS- and US- Guided Biopsy for Pancreatic Lesion is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: * Between January 2017 and December 2023, 2663 consecutive patients with focal pancreatic disease underwent 2729 procedures for pancreatic tissue acquisition from focal pancreatic lesions at…. Goal: Endoscopic ultrasound (EUS) and ultrasound (US) are the two primary imaging modalities used to guide pancreatic needle biopsy. This study aimed to compare the diagnostic performance and complications associated with EUS- and US-guided pancreatic biopsies. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tian'an Jiang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery is being studied. Conditions: Pancreatic Cancer, Surgery, Epidural Block +2 • Eligibility: Inclusion Criteria: 1. Age ≥45 and \<90 years; 2. Clinically diagnosed as resectable or possibly resectable pancreatic cancer and scheduled to undergo radical surgery; 3. Agreed to receive…. Goal: Pancreatic cancer remains a devastating disease with an average 5-year survival rate of about 3-5%. Previous retrospective studies showed that perioperative epidural block and/or dexamethasone are associated with improved outcome after cancer surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Peking University First Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC is being studied. Conditions: Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer • Eligibility: Inclusion Criteria: 1. Signed and dated informed consent document, willing and able to comply with protocol requirements, 2. Histologically or cytologically proven pancreatic ductal adenocarcinoma, 3. Age ≥…. Goal: TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance therapy in patients with advanced PDAC after induction therapy with FOLFIRINOX. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; GERCOR - Multidisciplinary Oncology Cooperative Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer is being studied. Conditions: Unresectable Biliary Tract Cancer • Eligibility: Inclusion Criteria: 1. Histologically documented locally advanced or metastatic BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) not previously treated with palliative systemic therapy or radiation…. Goal: You are being asked to take part in this study because you have a biliary cancer that is incurable and has spread to other organs. Chemotherapy is often used to help shrink the cancer temporarily and may improve survival. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests a radiopharmaceutical called 177Lu-CTR-FAPI for treating advanced metastatic gastrointestinal cancers that express fibroblast activation protein (FAP). It is for adults 18 to 75 with high FAP expression confirmed by 68Ga-FAPI PET/CT and at least one measurable tumor, and a good overall condition (ECOG 0-1). Researchers will assess safety, radiation dosimetry, and early signs of treatment activity. The study is single-centre, single-arm, non-blinded, plans to enroll about 20 patients, and is not yet recruiting; key exclusions include uncontrolled cancer-related conditions, significant organ or heart dysfunction, active infections (HBV/HCV/HIV), pregnancy, and inability to use contraception.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC) +2 • Eligibility: Inclusion Criteria: * Phase 1 Dose Escalation cohorts, Phase 1 Backfill cohorts, and Phase 2 Tumor Type-Specific cohort(s): must meet one of the following criteria: * HER2- metastatic…. Goal: NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nuvation Bio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * A female subject is eligible to participate if she is not pregnant or lactating and at least 1 of the following conditions applies: * Not…. Goal: Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is being studied. Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast • Eligibility: Inclusion Criteria: * Adults ≥18 years old. Other age restrictions may apply as per local regulations. * Unresectable and/or metastatic solid tumors with pre-specified HER2 mutations (S310F, S310Y,…. Goal: This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer is being studied. Conditions: Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Patients with histopathologic or cytologic diagnosis of adenocarcinoma of the pancreas (PDAC), or suspicious for malignancy per pathology, which is deemed BR or LA PDAC…. Goal: The purpose of this study is to find out if combining durvalumab with standard stereotactic ablative radiotherapy (SABR) is an effective treatment for people with locally advanced or borderline resectable pancreatic cancer. The researchers will also look at the safety of the combination treatment and any side effects it causes. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests Trilaciclib to protect the bone marrow from chemotherapy in people with advanced biliary tract cancer (cholangiocarcinoma) or pancreatic cancer. It is for adults 18 and older who need chemotherapy and have a confirmed diagnosis, with enough health and follow-up ability. The study aims to learn about Trilaciclib’s safety and whether it reduces chemotherapy-related bone marrow suppression. Major exclusions include history of certain myeloid blood disorders, active brain metastases, pregnancy or lactation, recent major surgery or radiotherapy, and known allergy to the study drug.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) +1 • Eligibility: Inclusion Criteria: * Must be ≥18 years of age * Must have histologically or cytologically confirmed diagnosis as follows: 1. Monotherapy Phase 1: A locally advanced unresectable or…. Goal: This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Immuneering Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving a Bile Duct Drainage Procedure in Patients With Inoperable Cancer Blocking the Bile Ducts: Comparing Two Types of Endoscopically Placed Internal Stents to Prevent Blockage of a Lumen Apposing Metal Stent is being studied. Conditions: Malignant Biliary Obstruction, Advanced Pancreatic Cancer and Cholangiocarcinoma, Inoperable Malignant Biliary Obstruction +1 • Eligibility: Inclusion Criteria: * Age ≥18 years. * Radiologically or histologically proven malignant distal bile duct obstruction with unresectable or metastatic disease, including those who have already failed ERCP…. Goal: This study looks at the best way to treat bile duct blockage in people with advanced cancer that cannot be removed by surgery. A blocked bile duct can cause serious symptoms like yellowing of the skin (jaundice), infection, and pain. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Waikato Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V +12 • Eligibility: Inclusion Criteria: * Has at least 1 of the 7 KRAS/NRAS mutated alleles (G12D, G12R, G12V, G12A, G12C, G12S, G13D) * The following must be met: (1) the…. Goal: This is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in patients with KRAS/NRAS-mutated pancreatic ductal adenocarcinoma who are at high risk for relapse (ie, presence of isolated tumor cells in a patient whose primary tumor has been removed and is currently without clinical signs of disease). This protocol builds on the experience being obtained with ELI-002 7P (with Amph-Peptides G12D, G12R, G12V, G12A, G12C, G12S, G13D), which is being studied in protocol ELI-002-201. Phase/Status/Sponsor: Unknown phase; AVAILABLE; Elicio Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: * Men or women 18 years of age or more * Newly diagnosed, in place tumors of the pancreas * No documented or observable psychiatric or…. Goal: The purpose of the study is to evaluate the feasibility and acceptability of a remote nutrition coaching and monitoring intervention during the 12-weeks of active chemotherapy for borderline resectable and locally advanced pancreatic cancer participants. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1/2 trial testing TC-510, a novel autologous engineered T cell therapy, in adults with advanced cancers that express mesothelin. TC-510 uses T cells modified with a mesothelin-targeting single-domain antibody fused to CD3 and a PD-1:CD28 switch receptor to boost activity against PD-L1–positive cancer cells. Eligible cancers include malignant pleural mesothelioma, serous ovarian adenocarcinoma, pancreatic adenocarcinoma, triple-negative breast cancer, and colorectal cancer, as long as the tumor shows mesothelin expression by immunohistochemistry. Participants must be 18 or older, have 1–5 prior systemic therapies for metastatic or unresectable disease, a good performance status (ECOG 0–1), be fit for leukapheresis, and have adequate organ function; key exclusions are inability to follow study procedures and known non-compliance or drug/alcohol use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy is being studied. Conditions: Metastatic Pancreatic Cancer • Eligibility: Inclusion Criteria: Prior/Concurrent Therapy Criteria 1. Patients must be initiating a new treatment regimen for pancreatic cancer at the time of their initiation in the study 2. Patients…. Goal: This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Northwell Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial is being studied. Conditions: Hepatocellular Carcinoma (HCC) • Eligibility: Inclusion Criteria: 1. Age 18 years or older, gender unlimited; 2. Subjects for whom sufficient blood samples can be obtained (whole blood volume not less than 10 mL);…. Goal: This clinical trial aims to systematically evaluate the clinical performance and accuracy of the HepaAiQ test kit, a multi-gene methylation assay based on PCR with fluorescent probe detection. The test results are compared against clinical reference standards, including pathological and/or imaging diagnoses, to assess the product's diagnostic performance. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Singlera Genomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) is being studied. Conditions: Pancreas Adenocarcinoma • Eligibility: Inclusion Criteria: 1. 18 years of age and older 2. Life expectancy of ≥ 3 months 3. Histological/cytological diagnosis of de novo adenocarcinoma of the pancreas 4. Unresectable,…. Goal: Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays. Phase/Status/Sponsor: Unknown phase; COMPLETED; NovoCure Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests peposertib together with avelumab and hypofractionated radiation therapy in adults with advanced or metastatic solid tumors and hepatobiliary cancers. - It aims to find a safe dose and assess how well this combination works, with Phase II focusing on hepatobiliary tumors and comparing against avelumab plus radiation alone by measuring objective response rate. - The study will also look at how the drugs are processed in the body and collect biomarker data to understand who may respond. - Eligibility notes include that Phase I excludes prior immune checkpoint therapy, while Phase II has some allowed prior checkpoint exposure under specific conditions; pregnancy is not allowed and certain autoimmune or CNS conditions exclude participation. - The study status is currently suspended.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Age ≥18 years. * Has pancreatic ductal adenocarcinoma * Has resectable disease at the time of diagnosis * Has not received any systemic therapy for…. Goal: This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody. Phase/Status/Sponsor: Unknown phase; COMPLETED; Lei Zheng.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested the [18F]FAPI-74 PET scan to detect FAP-expressing cells in people with gastrointestinal cancers, including liver cancer, cholangiocarcinoma, gastric, pancreatic, and colorectal cancer. - It enrolled adults with confirmed GI cancers and used the PET scan after initial staging, comparing PET results with FAP immunohistochemistry as the primary objective and with histopathology as the secondary objective. - Participants needed a tissue sample from biopsy or planned biopsy/resection, no cancer treatment between tissue sampling and the PET scan, and informed consent. - Exclusions included pregnancy or breastfeeding, infections or serious illnesses that could affect FAP expression, recent use of another investigational agent, and known hypersensitivity to components of the tracer. - The study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy is being studied. Conditions: Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer +2 • Eligibility: Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Diagnosed with non-small cell lung cancer (NSCLC) OR melanoma AND initiating therapy with single…. Goal: This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and negative clinical outcomes during checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Indiana University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tested whether adding hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil to biliary drainage improves survival for people with locally advanced, unresectable perihilar cholangiocarcinoma (pCCA). - It compared biliary drainage plus this chemotherapy approach against biliary drainage plus best supportive care. - Participants were adults aged 18–80 with locally advanced unresectable pCCA, good performance status, and adequate liver function; key exclusions included allergy to contrast or 5-FU, pregnancy, prior chemotherapy or radiotherapy, metastases, and serious comorbidities. - The study has completed and aimed to determine whether the combined treatment provides a survival benefit and acceptable safety.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface is being studied. Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms • Eligibility: Inclusion Criteria: * Signed and dated, written informed consent form (ICF) (ICF1 for B7-H6 testing for all patients except those with advanced or metastatic colorectal cancer (CRC); and…. Goal: This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Brightline-2 trial tests whether brigimadlin (BI 907828) helps adults with advanced cancer of the biliary tract, pancreas, lung, or bladder. It’s for people whose cancer has not responded to standard treatment or for whom no standard treatment exists. Brigimadlin is taken as a tablet every 3 weeks, with regular visits to monitor tumor size and safety. Eligibility requires specific tumor biology (MDM2 amplification or TP53 wild-type) confirmed by tissue testing and measurable disease with good performance status. Key exclusions include prior brigimadlin or other MDM2/MDMX-p53 drugs, risk of significant bleeding, or conditions that could make participation unsafe. The study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) is being studied. Conditions: PDAC - Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy * Patients able to undergo at least two…. Goal: The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). Phase/Status/Sponsor: Unknown phase; SUSPENDED; Cedars-Sinai Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung +2 • Eligibility: Inclusion Criteria: * Patients must have histological confirmation of solid metastatic cancer with at least one metastatic or primary lesion in the liver or lung/chest, except for group…. Goal: This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung/chest or liver cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma +2 • Eligibility: Key Inclusion Criteria: 1. Age ≥18 years. 2. Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma. 3.…. Goal: This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; CRISPR Therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ZW25 (zanidatamab) added to standard first-line chemotherapy in people with HER2-expressing gastrointestinal cancers that are unresectable or metastatic, specifically gastroesophageal adenocarcinoma, biliary tract cancer, or colorectal cancer. The study has two parts: Part 1 checks safety and tolerability and helps establish a recommended dose for the combination, and Part 2 evaluates the anti-tumor activity. Eligible participants have HER2-expressing tumors, are unresectable or metastatic, and have good performance status with adequate organ and heart function; colorectal cancer participants must have wild-type RAS/BRAF, with additional biomarker criteria by part. Key exclusions include prior HER2-targeted therapy, recent systemic cancer treatment (with limited exceptions), untreated brain metastases, significant cardiac disease, QTc prolongation, active infections, or uncontrolled HIV/HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tested whether tumor tissue and blood can identify biomarkers that predict how advanced biliary tract cancer responds to a chemotherapy combination of gemcitabine, cisplatin, and nab-paclitaxel. It enrolled adults with biliary tract cancer that is unresectable, metastatic, or recurrent, who planned to receive the triplet chemotherapy after tumor sequencing. Researchers used biopsy samples for in-house sequencing and collected blood over time to study cell-free DNA and circulating tumor cells and their relation to response and progression. Eligibility required measurable disease and good performance status, with key exclusions including uncontrolled illness, prior palliative chemotherapy for BTC, and dementia or other conditions affecting consent. Status: COMPLETED; Sponsor: CHA University; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Treatment Strategy for Adult Congenital Biliary Dilation is being studied. Conditions: Congenital Biliary Dilation • Eligibility: Inclusion Criteria ： 1. Age: Adults (≥18 years). 2. Study population: Consecutive patients treated at Beijing Tsinghua Changgung Hospital. 3. Time frame: Underwent surgical treatment between November 2014…. Goal: The management of congenital biliary dilations (CBDs), including choledochal cysts, represents one of the most challenging areas in hepatobiliary surgery due to their potential implications for long-term morbidity and malignant transformation. While CBDs have a relatively low incidence in Western populations (1/150,000-1/100,000), the prevalence is notably higher in Asian countries (1/1,000), making it a significant global health concern. Phase/Status/Sponsor: Unknown phase; COMPLETED; Beijing Tsinghua Chang Gung Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer is being studied. Conditions: Undernutrition, Gastrointestinal Cancer • Eligibility: Case group selection criteria: Inclusion Criteria: * 18 years ≤ Age ≤ 80 years * Colorectal pancreatic cancer * Undernutrition related to cancer (weight loss \> 5% weight…. Goal: Undernutrition associated with cancer, or cancer cachexia results from a deterioration of the energy balance that leads to a gradual mobilization of energy reserves in the body and to increasing deterioration of the nutritional status of patients. This will thus significantly reduce quality of life and survival of patients with a lower tolerance to cancer treatments. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Tours.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients is being studied. Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma +14 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; AVAILABLE; AVM Biotechnology Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The Liver and Biliary Tumor Tissue Registry collects tissue from adults having surgery to remove a liver or biliary mass or from those having a biopsy, to store for future research. - A blood sample may also be collected at enrollment. - The goal is to support translational research on the biology, causes, and prognosis of liver and biliary diseases, including studies that may use patient-derived xenografts. - Eligibility: people scheduled for surgical resection of a liver or biliary mass; Exclusions: under 18 years old or prior radiation to the mass. - Status: terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.